Research programme: purinoceptor P2X3 antagonists - NEOMED

Drug Profile

Research programme: purinoceptor P2X3 antagonists - NEOMED

Alternative Names: BLU-5937; NEO-5024; NEO-5937; P2X3 receptor antagonists - NEOMED

Latest Information Update: 25 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer NEOMED
  • Class Analgesics; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cough; Pain; Visceral pain
  • No development reported Interstitial cystitis

Most Recent Events

  • 09 Aug 2017 BELLUS Health announces intention to submit IND for BLU 5937 in 2018
  • 09 Aug 2017 BELLUS Health plans a phase I trial of BLU 5937 in the second half of 2018
  • 24 Apr 2017 BELLUS Health has patent protection for BLU 5937 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top